Medpace Soars After Q2 Beat, Strong Backlog Fuels 2026 Outlook - Medpace Holdings (NASDAQ:MEDP)
Medpace Holdings (NASDAQ:MEDP) reported Q2 EPS of $4.25 vs $3.97 consensus and revenue of $707.33M vs $687.65M. YoY revenue rose 17.2% with 24.1% backlog conversion. Project backlog grew 4.9% to over $3.01B. The company raised FY2026 EPS to $17.25-$17.95 and revenue to $2.805B-$2.885B.
How this was made
The 30-second read
Why it matters
The combination of Q2 beat, backlog growth to over $3.01B, net book-to-bill of 1.13x, and raised FY2026 EPS/revenue/EBITDA ranges provides a clear forward earnings catalyst.
Market read
Traders can reprice MEDP on the raised FY2026 ranges and backlog conversion metrics, which are directly tied to forward revenue and EBITDA.
What to watch
The article does not break out customer concentration, contract duration mix, or margin drivers beyond EBITDA growth, which could matter for follow-through.
Background
Medpace is a clinical contract research organization reporting Q2 results and updating FY2026 guidance.
Ticker impact
Medpace beat Q2 consensus on EPS ($4.25 vs $3.97) and sales ($707.33M vs $687.65M), then raised FY2026 guidance.
Near-term upside bias as raised guidance and backlog growth can extend the post-earnings rally, though volatility may persist after a large one-day move.
Guidance is explicitly increased with quantified ranges, and the backlog/net book-to-bill metrics provide a direct bridge to forward revenue conversion.
Market effects
Supports the CRO read-through that demand and backlog conversion remain healthy, potentially improving sentiment for clinical services peers.
Limited direct regional spillover; primarily US-listed CRO sentiment.
Moderate, as CRO backlog and guidance can influence global clinical outsourcing expectations.
Counterpoint
A large backlog and net bookings can still face timing risk in revenue recognition, so the raised ranges may not fully de-risk future quarters.
Key entities
- companyMedpace Holdings
Reported Q2 beat and raised fiscal 2026 EPS, revenue, and EBITDA guidance; backlog and net bookings increased.
- executiveAugust Troendle
CEO cited well-behaved cancellations and constructive environment into July.
